ClinicalTrials.gg
RecruitingNCT04774770Updated Apr 15, 2024

HED-Start: Evaluating a Positive Skills Intervention for Patients New on Haemodialysis

An interventional study of HED-Start in End Stage Renal Disease on Dialysis, End Stage Renal Failure on Dialysis and End Stage Renal Disease, sponsored by Nanyang Technological University. Recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by Nanyang Technological University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Kidney Failure, Chronic with a site in Singapore — 2 open to participants now, 2 under way, none of them phase 3. Kidney Failure, Chronic · Singapore.

Planned enrollment
6th of 16
148 · median 99
Started
2021
with 2 others
No phase
9 of 17
2 open now
Registered
12th of 17
by date
Lead sponsor
1 of 17
Nanyang Technological University

Among the 17 studies in Kidney Failure, Chronic with a site in Singapore, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2021, is one of 9 with no phase, and was the 12th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

2 of the 17 studies in Kidney Failure, Chronic with a site in Singapore are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Kidney Failure, Chronic with a site in Singapore, or all of them as a file.
02

Study summary

Hemodialysis patients often experience barriers and misperceptions that hinder adjustment to life on dialysis. This study seeks to explore a group-based intervention (titled HED-Start) developed to improve self-care and emotional wellbeing among incident hemodialysis patients.

Read the detailed description

There are potentially modifiable psychosocial barriers and misperceptions about life on dialysis that hinder adjustment outcomes. It is hypothesized that these may include: poor understanding on what is needed or 'how to implement treatment principles', misperceptions related to disease and treatment, catastrophizing beliefs about impact of dialysis and low level of confidence on ability to manage treatment regime and renegotiate life roles as a "dialysis patient".

This study seeks to explore the feasibility and acceptability of implementing a two-arm parallel randomized controlled trial of a group-based intervention (titled HED-Start). HED-Start is specifically developed to reduce psychological distress and support self-care and self-management outcomes in incident hemodialysis patients.

Drawing on self-management and motivational interviewing principles paradigm, the HED-Start program aims to facilitate acquisition of skills and knowledge to support and improve self-care and emotional adjustment outcomes.

03

Conditions studied

  • End Stage Renal Disease on Dialysis
  • End Stage Renal Failure on Dialysis
  • End Stage Renal Disease
  • End Stage Kidney Disease
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with end-stage kidney disease (ESKD) and established on hemodialysis with the National Kidney Foundation Singapore (NKF) for fewer than 90 days
  • At least 21 years old
  • Proficient in spoken and written English or Mandarin

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to give or refuse to be randomized
  • Have cognitive impairments or psychiatric conditions that preclude consent
  • Are currently involved in other intervention trials
  • Are failing on dialysis and approaching end of life (supportive/palliative care pathway)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    HED-Start Intervention arm

    Participants assigned to the intervention arm will undergo 4 sessions of the HED-Start program. Each session is 2 hours long and will be conducted fortnightly.

    Behavioral: HED-Start

  • No intervention
    Standard care arm

    Participants assigned to the standard care arm will proceed with routine standard care.

Interventions

  • BehavioralHED-Start

    The HED-Start Program is a cognitive-behavioral intervention based on self-management and motivational interviewing principles.

06

What researchers measure

Primary outcomes

  1. Change in Anxiety and Depression (HADS) scores from baseline

    Hospital Anxiety and Depression Scale (HADS). The HADS comprises two subscales (anxiety; depression) and can be totaled to produce an overall scale score. Scores range from 0 to 21 for each subscale, and from 0 to 42 for the overall score. Higher scores are indicative of worse anxiety and depression symptoms.

    Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization

Secondary outcomes

  1. Change in Quality of life (WHOQOL-BREF) scores from baseline

    World Health Organization Quality of Life instrument (WHOQOL-BREF). Two global items (overall quality of life; general health) and two subscales (psychological health; social relationships) from the WHOQOL-BREF are used. Global scores range from 1 to 5, while subscale scores range from 4 to 20. Higher scores indicate better quality of life.

    Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization

  2. Change in kidney disease-related quality of life (KDQOL-SF) scores from baseline

    Kidney Disease Quality of Life instrument (KDQOL-SF). The Burden of Kidney Disease subscale from the KDQOL-SF will be administered. Scores range from 0 to 100, with a higher score reflecting better quality of life.

    Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization

  3. Change in Illness Perception scores from baseline

    Brief Illness Perception Questionnaire (BIPQ). The BIPQ consists of 8 subscales (i.e., Consequence, Timeline, Identity, Personal Control, Treatment Control, Concern, Coherence, and Emotional Representation). Subscale scores range from 0 to 10, with higher scores reflective of more negative illness perceptions.

    Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization

  4. Change in Positive and Negative Affect scores from baseline

    Scale of Positive and Negative Experience (SPANE). The SPANE comprises 6 items assessing positive affect and 6 items assessing negative affect. Subscale scores range from 6 to 30. Higher scores in the Positive and Negative affect subscale indicate greater positive and negative affect respectively.

    Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization

  5. Change in Self-Efficacy for Managing Chronic Disease 6-item Scale scores from baseline

    Self-Efficacy for Managing Chronic Disease 6-item Scale. The overall scale score ranges from 1 to 10. Higher scores reflect greater self-efficacy.

    Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization

  6. Change in Benefit finding in hemodialysis (BFS) scores from baseline

    Benefit Finding Scale (BFS). Two subscales (personal growth; acceptance) and an overall score can be computed. All scores range from 1 to 4, with a higher score reflecting a greater extent of benefit finding.

    Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization

  7. Change in Resilience scores from baseline

    2-item Connor-Davidson Resilience Scale (CD-RISC-2). The CD-RISC-2 score ranges from 0 to 8. Higher scores indicate greater resilience.

    Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization

  8. Change in Health Education Impact Questionnaire scores from baseline

    Health Education Impact Questionnaire (heiQ). Six subscales from the heiQ (Positive and Active Engagement in Life, Skill and Technique Acquisition, Constructive Attitudes and Approaches, Self-Monitoring and Insight, Health Services Navigation, and Social Integration and Support) will be used to assess other self-management skills. Scores range from 1 to 4. Higher scores indicate greater proficiency with the relevant skill domain.

    Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization

07

Study locations

1 of 1 sites recruiting
  • National Kidney Foundation Singapore
    Singapore, Singapore
    Recruiting
08

References and documents

Publications

  • Griva K, Chia JMX, Goh ZZS, Wong YP, Loei J, Thach TQ, Chua WB, Khan BA. Effectiveness of a brief positive skills intervention to improve psychological adjustment in patients with end-stage kidney disease newly initiated on haemodialysis: protocol for a randomised controlled trial (HED-Start). BMJ Open. 2021 Sep 21;11(9):e053588. doi: 10.1136/bmjopen-2021-053588. PubMed 34548369 ↗

Individual participant data

Plan to share: Yes — All deidentified IPD that underlie results in a publication will be available upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Oct 2022, 21 months.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 21 months is close to that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2021
First posted
Mar 1, 2021
StartActual
Jan 5, 2021
Primary completionActual
Oct 7, 2022
CompletionEst.
Jun 30, 2024
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04774770
Lead sponsor
Nanyang Technological University
Collaborators
National Kidney Foundation
Responsible party
Konstadina Griva (Associate Professor of Health Psychology and Behavioural Medicine, Nanyang Technological University) — Principal investigator
First posted
Mar 1, 2021
Start date
Jan 5, 2021
Primary completion
Oct 7, 2022
Completion
Jun 30, 2024 (estimated)
Last update
Apr 15, 2024

Study contacts

Konstadina Griva, PhD
Contact
konstadina.griva@ntu.edu.sg
+6569047348
Konstadina Griva, PhD
principal investigator · Nanyang Technological University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion